目的探讨高度近视白内障患者爱尔康衍射型多焦点人工晶体（Acry Sof Restor）植入的临床应用效果。方法选取高度近视合并白内障患者40例（52眼）,分别植入AcrySofRestor渐进衍射型多焦点人工晶体（多焦组24例/32眼）和单焦点人工晶体（单焦组,16例/20眼）。术后3~6个月随访,观察术后两组患者的视力、视觉症状、视功能质量及对比敏感度情况。结果术后两组患者裸眼远视力、最佳矫正远视力、最佳矫正近视力差异无统计学意义（均P〉0.05）,多焦组的裸眼近视力、最佳矫正远视力下近视力、全程视力优于单焦组（均P〈0.05）;光晕眩光视觉不良症状多焦组发生率高于单焦组,但无统计学意义（P〉0.05）;多焦组脱镜率（96.88%）高于单焦组（65.00%）（P〈0.05）;术后3个月眩光及无眩光条件下低空间频率多焦组对比敏感度均明显低于单焦组（均P〈0.05）,多焦组中高空间频率对比敏感度均低于单焦组,但差异无统计学意义（P〉0.05）。结论爱尔康（Acry Sof Restor）多焦点人工晶体为患者提供了良好的远、近视力,提高了患者脱镜率,但空间对比敏感度有缺失。
Folic acid conjugated chitosan was prepared by cross-linking reaction with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride(EDC), and then used as a template to prepare folic acid-chitosan(FA-CS) conjugated nanoparticles and load mitoxantrone nanoparticles(FA-CSNP/MTX). Drug dissolution testing, CCK-8 method, and confocal microscopy were used to detect their controlled-release capability in different situations and the specific uptake by HONE1 cells. The experimental results show that the nanoparticles have uniform size distribution of 48-58 nm. The highest encapsulation rate of the particles on mitoxantrone hydrochloride(MTX) is(77.5±1.9)%, and the drug loading efficiency is(18.4±0.4)%. The sustained release effect, cell growth inhibition activity and targeting effect of the FA-CS/MTX nanoparticles are good in artificial gastric fluid and intestinal fluid. It is demonstrated that the FA-CSNP system is a potentially useful system for the targeted delivery of anticancer drug MTX.
